Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on addressing severe diseases through RNA-based therapies, is set to present promising clinical data on its leading candidate, zorevunersen (STK-001), at the 15th European Epilepsy Congress (EEC) in Rome, Italy, from September 7 to 11, 2024. This presentation aims to highlight zorevunersen’s potential as the first disease-modifying treatment for Dravet syndrome, a rare and severe form of epilepsy that often leads to frequent seizures, developmental delays, and increased mortality risk in affected children.
Zorevunersen is an innovative antisense oligonucleotide (ASO) designed to target the underlying genetic causes of Dravet syndrome by enhancing protein expression. Stoke Therapeutics emphasizes its commitment to developing therapies that not only alleviate symptoms but also modify the disease course itself. This pivotal data presentation at the EEC will represent a significant moment in the ongoing development of RNA-based treatments for neurological disorders.
In addition to the upcoming European Epilepsy Congress presentation, Stoke Therapeutics has outlined its engagement with the investment community, planning to participate in notable conferences including the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, and the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024. These engagements signify the company’s commitment to transparency and investment in research and development, as it seeks to rally support for its innovative initiatives aimed at addressing the root causes of significant genetic diseases.
As Stoke Therapeutics continues to pave the way for groundbreaking therapies in the field of RNA medicine, the company anticipates that the forthcoming presentations will garner attention from both the scientific community and potential investors, ultimately accelerating the development of treatments that hold the promise of improving patient outcomes in conditions like Dravet syndrome.
Comments